Functional impairments for outcomes in a randomized trial of unruptured brain AVMs

J. P. Mohr, Jessica R. Overbey, Ruediger Von Kummer, Marco A. Stefani, Richard Libman, Christian Stapf, Michael K. Parides, John Pile-Spellman, Ellen Moquete, Claudia S. Moy, Eric Vicaut, Alan J. Moskowitz, Kirsty Harkness, Charlotte Cordonnier, Alessandra Biondi, Emmanuel Houdart, Joachim Berkefeld, Catharina J.M. Klijn, Xavier Barreau, Helen KimAndreas Hartmann

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To investigate the effects of medical vs interventional management on functional outcome in A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA). Methods: We used the initial results of a nonblinded, randomized, controlled, parallel-group trial involving adults ≥18 years of age with an unruptured brain arteriovenous malformation (AVM) to compare the effects of medical management (MM) with or without interventional therapy (IT) on functional impairment, defined by a primary outcome of death or symptomatic stroke causing modified Rankin Scale (mRS) score ≥2. ARUBA closed recruitment on April 15, 2013. Results: After a median of 33.3 months of follow-up (interquartile range 16.3-49.8 months), of the 223 enrolled in the trial, those in the MM arm were less likely to experience primary outcomes with an mRS score ≥2 than those who underwent IT. The results applied for both those as randomized (MM n = 109 vs IT n = 114) (hazard ratio [HR] 0.25, 95% confidence interval [CI] 0.11-0.57, p = 0.001) and as treated (MM n = 125 vs IT n = 98) (HR 0.10, 95% CI 0.04-0.28, p < 0.001). Functional impairment for the outcomes showed no significant difference by Spetzler-Martin grade for MM but was more frequent with increasing grades for IT (p < 0.001). Conclusion: Death or stroke with functional impairment in ARUBA after a median follow-up of 33 months was significantly lower for those in the MM arm both as randomized and as treated compared with those with IT. Functional severity of outcomes was lower in the MM arm, regardless of Spetzler-Martin grades. ClinicalTrials.gov identifier: NCT00389181. Classification of evidence: This study provides Class II evidence that for adults with unruptured brain AVMs, interventional management compared to MM increases the risk of disability and death over ≈3 years.

Original languageEnglish (US)
Pages (from-to)1499-1506
Number of pages8
JournalNeurology
Volume89
Issue number14
DOIs
StatePublished - Oct 3 2017
Externally publishedYes

Fingerprint

Arteriovenous Malformations
Brain
Therapeutics
Stroke
Confidence Intervals
Risk Management

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Mohr, J. P., Overbey, J. R., Von Kummer, R., Stefani, M. A., Libman, R., Stapf, C., ... Hartmann, A. (2017). Functional impairments for outcomes in a randomized trial of unruptured brain AVMs. Neurology, 89(14), 1499-1506. https://doi.org/10.1212/WNL.0000000000004532

Functional impairments for outcomes in a randomized trial of unruptured brain AVMs. / Mohr, J. P.; Overbey, Jessica R.; Von Kummer, Ruediger; Stefani, Marco A.; Libman, Richard; Stapf, Christian; Parides, Michael K.; Pile-Spellman, John; Moquete, Ellen; Moy, Claudia S.; Vicaut, Eric; Moskowitz, Alan J.; Harkness, Kirsty; Cordonnier, Charlotte; Biondi, Alessandra; Houdart, Emmanuel; Berkefeld, Joachim; Klijn, Catharina J.M.; Barreau, Xavier; Kim, Helen; Hartmann, Andreas.

In: Neurology, Vol. 89, No. 14, 03.10.2017, p. 1499-1506.

Research output: Contribution to journalArticle

Mohr, JP, Overbey, JR, Von Kummer, R, Stefani, MA, Libman, R, Stapf, C, Parides, MK, Pile-Spellman, J, Moquete, E, Moy, CS, Vicaut, E, Moskowitz, AJ, Harkness, K, Cordonnier, C, Biondi, A, Houdart, E, Berkefeld, J, Klijn, CJM, Barreau, X, Kim, H & Hartmann, A 2017, 'Functional impairments for outcomes in a randomized trial of unruptured brain AVMs', Neurology, vol. 89, no. 14, pp. 1499-1506. https://doi.org/10.1212/WNL.0000000000004532
Mohr JP, Overbey JR, Von Kummer R, Stefani MA, Libman R, Stapf C et al. Functional impairments for outcomes in a randomized trial of unruptured brain AVMs. Neurology. 2017 Oct 3;89(14):1499-1506. https://doi.org/10.1212/WNL.0000000000004532
Mohr, J. P. ; Overbey, Jessica R. ; Von Kummer, Ruediger ; Stefani, Marco A. ; Libman, Richard ; Stapf, Christian ; Parides, Michael K. ; Pile-Spellman, John ; Moquete, Ellen ; Moy, Claudia S. ; Vicaut, Eric ; Moskowitz, Alan J. ; Harkness, Kirsty ; Cordonnier, Charlotte ; Biondi, Alessandra ; Houdart, Emmanuel ; Berkefeld, Joachim ; Klijn, Catharina J.M. ; Barreau, Xavier ; Kim, Helen ; Hartmann, Andreas. / Functional impairments for outcomes in a randomized trial of unruptured brain AVMs. In: Neurology. 2017 ; Vol. 89, No. 14. pp. 1499-1506.
@article{13dda8a5c4e24f468b0b3597e52599a6,
title = "Functional impairments for outcomes in a randomized trial of unruptured brain AVMs",
abstract = "Objective: To investigate the effects of medical vs interventional management on functional outcome in A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA). Methods: We used the initial results of a nonblinded, randomized, controlled, parallel-group trial involving adults ≥18 years of age with an unruptured brain arteriovenous malformation (AVM) to compare the effects of medical management (MM) with or without interventional therapy (IT) on functional impairment, defined by a primary outcome of death or symptomatic stroke causing modified Rankin Scale (mRS) score ≥2. ARUBA closed recruitment on April 15, 2013. Results: After a median of 33.3 months of follow-up (interquartile range 16.3-49.8 months), of the 223 enrolled in the trial, those in the MM arm were less likely to experience primary outcomes with an mRS score ≥2 than those who underwent IT. The results applied for both those as randomized (MM n = 109 vs IT n = 114) (hazard ratio [HR] 0.25, 95{\%} confidence interval [CI] 0.11-0.57, p = 0.001) and as treated (MM n = 125 vs IT n = 98) (HR 0.10, 95{\%} CI 0.04-0.28, p < 0.001). Functional impairment for the outcomes showed no significant difference by Spetzler-Martin grade for MM but was more frequent with increasing grades for IT (p < 0.001). Conclusion: Death or stroke with functional impairment in ARUBA after a median follow-up of 33 months was significantly lower for those in the MM arm both as randomized and as treated compared with those with IT. Functional severity of outcomes was lower in the MM arm, regardless of Spetzler-Martin grades. ClinicalTrials.gov identifier: NCT00389181. Classification of evidence: This study provides Class II evidence that for adults with unruptured brain AVMs, interventional management compared to MM increases the risk of disability and death over ≈3 years.",
author = "Mohr, {J. P.} and Overbey, {Jessica R.} and {Von Kummer}, Ruediger and Stefani, {Marco A.} and Richard Libman and Christian Stapf and Parides, {Michael K.} and John Pile-Spellman and Ellen Moquete and Moy, {Claudia S.} and Eric Vicaut and Moskowitz, {Alan J.} and Kirsty Harkness and Charlotte Cordonnier and Alessandra Biondi and Emmanuel Houdart and Joachim Berkefeld and Klijn, {Catharina J.M.} and Xavier Barreau and Helen Kim and Andreas Hartmann",
year = "2017",
month = "10",
day = "3",
doi = "10.1212/WNL.0000000000004532",
language = "English (US)",
volume = "89",
pages = "1499--1506",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

TY - JOUR

T1 - Functional impairments for outcomes in a randomized trial of unruptured brain AVMs

AU - Mohr, J. P.

AU - Overbey, Jessica R.

AU - Von Kummer, Ruediger

AU - Stefani, Marco A.

AU - Libman, Richard

AU - Stapf, Christian

AU - Parides, Michael K.

AU - Pile-Spellman, John

AU - Moquete, Ellen

AU - Moy, Claudia S.

AU - Vicaut, Eric

AU - Moskowitz, Alan J.

AU - Harkness, Kirsty

AU - Cordonnier, Charlotte

AU - Biondi, Alessandra

AU - Houdart, Emmanuel

AU - Berkefeld, Joachim

AU - Klijn, Catharina J.M.

AU - Barreau, Xavier

AU - Kim, Helen

AU - Hartmann, Andreas

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Objective: To investigate the effects of medical vs interventional management on functional outcome in A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA). Methods: We used the initial results of a nonblinded, randomized, controlled, parallel-group trial involving adults ≥18 years of age with an unruptured brain arteriovenous malformation (AVM) to compare the effects of medical management (MM) with or without interventional therapy (IT) on functional impairment, defined by a primary outcome of death or symptomatic stroke causing modified Rankin Scale (mRS) score ≥2. ARUBA closed recruitment on April 15, 2013. Results: After a median of 33.3 months of follow-up (interquartile range 16.3-49.8 months), of the 223 enrolled in the trial, those in the MM arm were less likely to experience primary outcomes with an mRS score ≥2 than those who underwent IT. The results applied for both those as randomized (MM n = 109 vs IT n = 114) (hazard ratio [HR] 0.25, 95% confidence interval [CI] 0.11-0.57, p = 0.001) and as treated (MM n = 125 vs IT n = 98) (HR 0.10, 95% CI 0.04-0.28, p < 0.001). Functional impairment for the outcomes showed no significant difference by Spetzler-Martin grade for MM but was more frequent with increasing grades for IT (p < 0.001). Conclusion: Death or stroke with functional impairment in ARUBA after a median follow-up of 33 months was significantly lower for those in the MM arm both as randomized and as treated compared with those with IT. Functional severity of outcomes was lower in the MM arm, regardless of Spetzler-Martin grades. ClinicalTrials.gov identifier: NCT00389181. Classification of evidence: This study provides Class II evidence that for adults with unruptured brain AVMs, interventional management compared to MM increases the risk of disability and death over ≈3 years.

AB - Objective: To investigate the effects of medical vs interventional management on functional outcome in A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA). Methods: We used the initial results of a nonblinded, randomized, controlled, parallel-group trial involving adults ≥18 years of age with an unruptured brain arteriovenous malformation (AVM) to compare the effects of medical management (MM) with or without interventional therapy (IT) on functional impairment, defined by a primary outcome of death or symptomatic stroke causing modified Rankin Scale (mRS) score ≥2. ARUBA closed recruitment on April 15, 2013. Results: After a median of 33.3 months of follow-up (interquartile range 16.3-49.8 months), of the 223 enrolled in the trial, those in the MM arm were less likely to experience primary outcomes with an mRS score ≥2 than those who underwent IT. The results applied for both those as randomized (MM n = 109 vs IT n = 114) (hazard ratio [HR] 0.25, 95% confidence interval [CI] 0.11-0.57, p = 0.001) and as treated (MM n = 125 vs IT n = 98) (HR 0.10, 95% CI 0.04-0.28, p < 0.001). Functional impairment for the outcomes showed no significant difference by Spetzler-Martin grade for MM but was more frequent with increasing grades for IT (p < 0.001). Conclusion: Death or stroke with functional impairment in ARUBA after a median follow-up of 33 months was significantly lower for those in the MM arm both as randomized and as treated compared with those with IT. Functional severity of outcomes was lower in the MM arm, regardless of Spetzler-Martin grades. ClinicalTrials.gov identifier: NCT00389181. Classification of evidence: This study provides Class II evidence that for adults with unruptured brain AVMs, interventional management compared to MM increases the risk of disability and death over ≈3 years.

UR - http://www.scopus.com/inward/record.url?scp=85030763317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030763317&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000004532

DO - 10.1212/WNL.0000000000004532

M3 - Article

C2 - 28878048

AN - SCOPUS:85030763317

VL - 89

SP - 1499

EP - 1506

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 14

ER -